Cyheptamide
Cyheptamide was a investigational new drug that was developed by Ayerst Research Laboratories in the 1960s and was evaluated as an anticonvulsant.
Cyheptamide undergoes significant metabolic transformation in both animals and humans, primarily through hydroxylation pathways.
Cyheptamide exhibits moderate acute toxicity in animal models, with species-specific variations in lethal dose values.
Another agent that is creditworthy of consideration is called SGB-017 .